Octapharma USA sponsors ASA Symposium on fibrinogen supplementation in surgical patients

November 05, 2019

HOBOKEN, N.J. (November 5, 2019) - Octapharma USA sponsored a scientific symposium, "Fibrinogen Supplementation in Surgical Patients - New Perspectives in Acquired Fibrinogen Deficiency," at the recent American Society of Anesthesiologists Annual Meeting.

The symposium addressed the global perspectives on patient blood management with respect to fibrinogen replacement in acquired bleeding and treatment options for acquired fibrinogen deficiency (AFD). Researchers discussed the most recent results coming from new clinical studies that are being performed in acquired fibrinogen deficiency patients comparing the efficacy and safety of a human fibrinogen concentrate, fibryga®, and cryoprecipitate in the management of perioperative bleeding. Fibryga® is currently indicated for congenital fibrinogen deficiency. The clinical trials discussed at ASA include:"The studies presented at the symposium are important contributions to build on the current published research and growing clinical experiences with fibrinogen concentrates for managing bleeding in surgical patients," said Jerrold Levy, M.D., Symposium Chairman and Professor of Anesthesiology and Surgery, and Co-Director of the Cardiothoracic Surgical Intensive Care Unit at Duke University Medical Center in Durham, N.C.

"These two important clinical trials investigating the use of fibryga® in acquired fibrinogen deficiency have identified fibrinogen concentrate as a potential alternative to cryoprecipitate during severe surgical bleeding," said Octapharma USA President Flemming Nielsen. "The studies provide important data on fibryga® as a potential alternative to cryoprecipitate in helping doctors to restore normal fibrinogen levels. The FIBRES study has just been published online by the Journal of the American Medical Association (JAMA) and the PMP study has been accepted by the Journal of Thrombosis and Haemostasis with publication expected by the end of the year." 1, 2

Individual optimization of coagulation in the bleeding surgical patient plays a central role for successful patient blood management. Development of hypofibrinogenemia is an important contributor to coagulopathic bleeding complications. In cases of excessive bleeding and acquired hypofibrinogenemia, the Practice Guidelines for Perioperative Blood Management: An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management suggest treatment with either cryoprecipitate or fibrinogen concentrate.3
-end-
About fibryga®

Fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use, is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Fibryga® is not indicated for dysfibrinogenemia.

CONTRAINDICATIONSFibryga® is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis, to fibryga® or its components.

WARNINGS AND PRECAUTIONSThe fibryga® manufacturing process includes a solvent/detergent (S/D) step for virus inactivation, and a nanofiltration step (Planova 20N nanofilter or Pegasus SV4 nanofilter) for virus removal. For complete prescribing information, please visit fibrygausa.com.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 8,314 people worldwide to support the treatment of patients in over 115 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company's American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates three state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit http://www.octapharmausa.com.

REFERENCES

1 - Phase 2 Study of Fibrinogen Concentrate vs. Cryoprecipitate in Pseudomyxoma Peritonei Surgery: Interim Results, American Society of Anesthesiologists Annual Meeting, poster presentation, October 15, 2018.

2 - Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs. Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA. Published online October 21, 2019. doi:10.1001/jama.2019.17312.

3 - Practice Guidelines for Perioperative Blood Management: An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology 2015;122(2):241-275.MEDIA CONTACT:

Anita Callari
Yankee Public Relations
anita@yankeepr.com
908-425-4878

Yankee Public Relations

Related Cardiac Surgery Articles from Brightsurf:

New surgical tools with smart sensors can advance cardiac surgery and therapy
Researchers developed a new class of medical instruments equipped with an advanced soft electronics system that could dramatically improve the diagnoses and treatments of a number of cardiac diseases and conditions.

How commonly do patients develop persistent opioid use after cardiac surgery?
A large, national database was used to determine how common it was for patients who hadn't used opioids before undergoing a coronary artery bypass grafting or heart valve procedure to subsequently develop persistent opioid use after surgery.

Preoperative levels of heart proteins may help predict death or cardiac complications in patients undergoing noncardiac surgery
Assessing preoperative levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of heart stress and structural changes, may improve risk prediction beyond the clinical risk score in patients having noncardiac surgery.

Study finds connection between cardiac blood test before surgery and adverse outcomes
The VISION study looked at whether levels of a cardiac blood test, NT-proBNP, measured before surgery can predict cardiac and vascular complications.

Mayo Clinic study: 20% of patients are prescribed opioids after cardiac device implantation surgery
One in five patients is prescribed opioids after having a pacemaker or similar device implanted, according to a large US study conducted at Mayo Clinic published in HeartRhythm.

Careful monitoring of children following cardiac surgery may improve long-term outcomes
In a medical records study covering thousands of children, a US-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function.

Chest cavity fire during emergency cardiac surgery
At this year's Euroanaesthesia Congress (the annual meeting of the European Society of Anaesthesiology) in Vienna, Austria (1-3 June), doctors present the unique case of a man who suffered a flash fire in his chest cavity during emergency heart surgery caused by supplemental oxygen leaking from a ruptured lung.

Steroid use during cardiac bypass surgery did not reduce risk of severe kidney injury
Using steroids during cardiopulmonary bypass surgery did not reduce the risk of acute kidney injury in people at increased risk of death, according to a study conducted in 18 countries published in CMAJ (Canadian Medical Association Journal).

Cardiac surgery for patients with persistent opioid use associated with higher rate of complications, increased costs
Persistent use of opioids by patients is a public health concern in the United States but not much is known about the effect of that use on patients undergoing cardiac surgery.

Blood thinner significantly reduces the risk of death after non-cardiac surgery
The study enrolled 1,754 patients in 19 countries, 51 percent of whom were male, with an average age of 70 years.

Read More: Cardiac Surgery News and Cardiac Surgery Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.